Divergent Investments — Full Portfolio
6 tracked investments · listed companies and verified rows first
HealthtechMinneapolis, US
Christopher Olmanson(Executive Officer, Director)inMarissa Pittard(Executive Officer, Director)
BoardJon Bassett(Director)in
Co-investorsDesigner FundFlare Capital PartnersMoai CapitalNextGen Venture PartnersTau VenturesMedMountain Ventures+1 more
Learnfully is a personalized learning platform focused on neurodiverse learners, addressing executive dysfunction underlying challenges linked to conditions such as ADHD and dyslexia.
AI & Machine LearningEdTech
Co-investorsFigure 8 Investments
BiotechNorth Brunswick, US
Manish Arora(Executive Officer, Director)
BoardRafi Syed(Director)Amol Deshpande(Director)Ashok Krishnamurthi(Director)in
Co-investorsBow CapitalGreatPoint Ventures
LinusBio develops precision medicine diagnostics based on exposome sequencing to identify biomarkers for complex conditions including autism spectrum disorder, amyotrophic lateral sclerosis, inflammatory bowel disease, and other diseases.
AI & Machine LearningBiotechDigital HealthMedical DevicesNew York, US
Manish Arora(Founder and CEO)in
Co-investorsBow CapitalGPVGreatPoint Ventures
Marker Learning provides software tools to special education departments for conducting student evaluations more efficiently and accessibly.
AI & Machine LearningEdTechHealthtechSaaS
Emily(Co-founder)Stefan Bauer(Co-Founder and CEO)inDr. Samuel O. Ortiz(Chief Clinical Officer)
Co-investorsAndreessen HorowitzBONDCherry VenturesEdovate CapitalExpafirstminute capital+9 more
Opya provides early intervention ABA (applied behavior analysis) therapy for young children diagnosed with autism and their families.
Digital HealthHealthtechMental HealthCalifornia, US
Jonathan Wright(Founder)inChristina Sanders(Chief Executive Officer)inBrad Kerfetter(CFO)Keiko Ikeda(Chief Clinical Officer)inVivian Creasy(COO)in
Co-investorsBIP VenturesOpen Opportunity FundSPRINGROCK VENTURESPanoramic VenturesRaven One VenturesSoftBank Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.